Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 24123 | 7.68 |
09:34 ET | 15328 | 7.72 |
09:36 ET | 2509 | 7.73 |
09:38 ET | 3300 | 7.735 |
09:39 ET | 61507 | 7.69 |
09:41 ET | 1320 | 7.7002 |
09:43 ET | 1300 | 7.68 |
09:45 ET | 2414 | 7.71 |
09:48 ET | 1700 | 7.71 |
09:50 ET | 2029 | 7.6996 |
09:52 ET | 13572 | 7.68 |
09:54 ET | 7061 | 7.69 |
09:56 ET | 4135 | 7.73 |
09:57 ET | 969 | 7.715 |
09:59 ET | 1200 | 7.67 |
10:01 ET | 5690 | 7.695 |
10:03 ET | 700 | 7.72 |
10:06 ET | 9493 | 7.77 |
10:08 ET | 900 | 7.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.5B | -47.2x | --- |
Viking Therapeutics Inc | 5.2B | -51.8x | --- |
Nuvalent Inc | 5.2B | -32.4x | --- |
Immunitybio Inc | 5.0B | -6.2x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -11.9x | --- |
Krystal Biotech Inc | 5.2B | 96.7x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.